v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Jun. 30, 2017
Current assets:    
Cash $ 15,934 $ 8,088
Accounts receivable - trade 75 175
Work in process 0 26
Prepaid expenses and other current assets 276 283
Total Current Assets 16,285 8,572
Fixed assets, net of accumulated depreciation 25,152 25,589
Intangible assets, net of accumulated amortization 1,620 1,823
Security deposit 26 26
Total Assets 43,083 36,010
Current liabilities:    
Accounts payable (related party of $189 and $87 as of June 30, 2018 and 2017, respectively) 790 749
Accrued expenses (related party of $789 and $650 as of June 30, 2018 and 2017, respectively) 1,048 924
Capital lease obligation - current portion 197 183
Deferred revenue 0 157
Total Current Liabilities 2,035 2,013
Capital lease obligation - net of current portion 24,884 25,082
Total Liabilities 26,919 27,095
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 and 175,000,000 shares authorized as of June 30, 2018 and 2017, respectively; 16,040,126 and 8,911,851 shares issued and outstanding as of June 30, 2018 and 2017, respectively 16 9
Additional paid-in capital 104,408 81,057
Accumulated other comprehensive loss (30) (29)
Accumulated deficit (88,228) (72,123)
Total iBio, Inc. Stockholders' Equity 16,166 8,914
Noncontrolling interest (2) 1
Total Equity 16,164 8,915
Total Liabilities and Equity 43,083 36,010
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0

Source

v3.10.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Revenues $ 444 $ 394
Operating expenses:    
Research and development (related party of $877 and $957), net of grant income of $44 and $131 3,986 4,117
General and administrative (related party of $942 and $775) 10,685 10,551
Total operating expenses 14,671 14,668
Operating loss (14,227) (14,274)
Other income (expense):    
Interest expense (related party of $1,915 and $1,928) (1,915) (1,929)
Interest income 15 39
Royalty income 19 25
Total other income (expense) (1,881) (1,865)
Consolidated net loss (16,108) (16,139)
Net loss attributable to noncontrolling interest 3 1,607
Net loss attributable to iBio, Inc. (16,105) (14,532)
Preferred stock dividends (260) (90)
Net loss available to iBio, Inc. (16,365) (14,622)
Comprehensive loss:    
Consolidated net loss (16,108) (16,139)
Other comprehensive loss - foreign currency translation adjustments (1) 0
Comprehensive loss $ (16,109) $ (16,139)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (1.54) $ (1.64)
Weighted-average common shares outstanding - basic and diluted 10,631 8,911

Source

v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Consolidated net loss $ (16,108) $ (16,139)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 770 1,010
Amortization of intangible assets 341 350
Depreciation 1,368 1,326
Bad debt expense 61 0
Changes in operating assets and liabilities    
Accounts receivable - trade 39 309
Accounts receivable - unbilled 0 122
Work in process 26 (4)
Prepaid expenses and other current assets 8 (19)
Security deposit 0 2
Accounts payable 49 (257)
Accrued expenses 124 4
Deferred revenue (158) 133
Net cash used in operating activities (13,480) (13,163)
Cash flows from investing activities:    
Additions to intangible assets (145) (270)
Purchases of fixed assets (934) (1,323)
Net cash used in investing activities (1,079) (1,593)
Cash flows from financing activities:    
Proceeds from sales of preferred and common stock 21,621 0
Costs to raise capital (1,175) 0
Proceeds from additional paid-in capital - preferred stock 1,050 0
Proceeds from capital contribution 1,093 0
Payment of capital lease obligation (183) (170)
Net cash provided by (used in) financing activities 22,406 (170)
Effect of exchange rate changes (1) 0
Net increase (decrease) in cash 7,846 (14,926)
Cash - beginning of year 8,088 23,014
Cash - end of year 15,934 8,088
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 2 7
Intangible assets included in accounts payable in prior period, paid in current period 7 0
Unpaid fixed assets included in accounts payable 84 87
Fixed assets included in accounts payable in prior period, paid in current period 87 71
Issuance of preferred stock for acquisition of additional interest in subsidiary 0 12,499
Supplemental cash flow information:    
Cash paid during the year for interest $ 1,917 $ 1,930

Source